 |
Versant Ventures Announces Closing of $500 Million Venture Fund
Medical Devices and Biotechnology Continue as Focus of Versant Fund IV
Menlo Park, CA—July 31, 2008—Versant Ventures, a leading early-stage
healthcare venture capital firm, today announced the closing of Versant
Venture Capital IV, L.P., a $500 M fund. The firm now has more than $1.6
B and 75 portfolio companies under management, spanning biotechnology,
pharmaceuticals, and medical devices.
“We are proud to continue to partner with visionary entrepreneurs who
are building companies that are transforming healthcare. An
extraordinary number of unmet clinical needs remain in healthcare, and
we look forward to continuing to be a springboard for these meaningful
innovations,“ said Brian Atwood, Managing Director.
Versant IV will target approximately 30-35 medical device, biotech, and
pharmaceutical investments throughout the U.S. While the fund’s
investments will be primarily focused on early-stage and seed
opportunities, a limited number may also target later-stage companies as
well. “The $500 M fund size will enable us to support a full range of
entrepreneurial initiatives—from a few hundred thousand dollar seed to a
$20 M investment over the full life of the company,” said Kevin
Wasserstein, Managing Director.
Versant IV’s Managing Directors include, Brian Atwood, Brad Bolzon,
Ph.D., Sam Colella, Ross Jaffe, M.D., Bill Link, Ph.D., Robin Praeger,
Beckie Robertson, Camille Samuels, Charles Warden and Kevin Wasserstein.
The investment team also includes Kirk Nielsen, Principal, and Sammy
Farah, Ph.D., Associate.
About Versant Ventures
Since its formation in 1999, Versant Ventures, a premier early-stage
healthcare venture firm, has invested in over 95 healthcare companies
that have made important clinical contributions across a breadth of
therapeutic areas. Some examples of recent impact companies include:
LipoSonix, Inc.; St. Francis Medical Technologies, Inc.; NovaCardia,
Inc.; Pharmion Corp.; Eyeonics, Inc.; and a number of now-current public
companies including Genomic Health (GHDX); Insulet Corp. (PODD); and
Cadence Pharmaceuticals, Inc. (CADX). Versant’s two primary offices are
in Menlo Park and Newport Beach, California. For more information,
please visit www.versantventures.com.
For More Information Contact
Brian Atwood or Kevin Wasserstein
Managing Directors, Versant Ventures
650-233-7877
or
Jennifer Jones
650-529-1416
|
|
